Two prescriptions, handed over in the same appointment, and no explanation of how they relate. The obvious inference is that they are a pair — a PCOS regimen, the way an antibiotic course is a regimen — and that inference is what sends people to search for the two names together.
They are not a pair. In the 2023 international guideline they sit in different sections, answering different questions, and being offered both usually means two separate things are being addressed rather than one thing being attacked twice.
This page does not tell you what to take, and it names no doses. It is about which question each drug is the answer to, because that is the part that is almost never said out loud and the part that makes the next appointment easier.
The three medications, and the question each one answers
| What the guideline positions it for | Where it sits | |
|---|---|---|
| Combined oral contraceptive pill | Menstrual irregularity and hyperandrogenism | First-line pharmacological management; no particular preparation named as superior |
| Metformin | Metabolic features | Recommended over the pill for metabolic indications |
| Anti-androgens (spironolactone among them) | Hirsutism | Limited role — where the pill is contraindicated, poorly tolerated, or ineffective beyond six months |
The guideline makes the split explicit rather than leaving it to be inferred: combined oral contraceptives over metformin for irregular cycles and hirsutism, and metformin over combined oral contraceptives for metabolic indications. Two different answers, chosen by what is being treated.
Read that table back and the pairing stops being mysterious. Someone taking metformin and spironolactone is being treated for a metabolic indication and for hirsutism where the pill was not the route — two problems, two answers, arriving in the same envelope.
Where metformin sits
Metformin is recommended primarily for metabolic features. Not for cycles, not for hair, not as a general-purpose PCOS drug — for the metabolic side of the condition, which the guideline takes seriously enough to ask for glycaemic screening in everyone with the diagnosis, at any weight.
The guideline also puts it above inositol on evidence: metformin has greater efficacy, and inositol offers limited clinical benefit. That comparison is worth knowing because the two are constantly discussed as interchangeable, one a prescription and one available in any pharmacy, as though the only difference were how you obtain them.
If metformin was prescribed and nobody said why, metabolic is the likeliest answer, and “which metabolic finding is this for?” is a question with a specific answer in your notes.
Where spironolactone sits, and what the six months is about
Anti-androgens have a limited role. That phrase is the guideline’s, and it is doing real work: it means not first, and not routinely.
The routes in are specific. Possible benefit for hirsutism, where combined oral contraceptives are contraindicated, poorly tolerated, or have been ineffective for over six months — with clinical context, individual needs and risk factors considered.
The six months is not bureaucratic patience. Hair grows in cycles, and a follicle already committed to a growth phase is unaffected by anything started today; the change shows up as the next cycle begins, across months. Judging any treatment for hirsutism at six weeks measures the follicles’ old instructions, not the new ones. That timescale is brutal when the symptom is one you see in the mirror daily, and it is the reason a treatment can be working and invisible at the same time.
The contraception requirement is not optional detail
Anti-androgens are used with effective contraception where pregnancy is not intended, and the reason is worth stating plainly rather than leaving as fine print.
Androgens drive the development of a male fetus during a specific window in early pregnancy. A drug whose entire mechanism is blocking androgen effects can interfere with that process. The requirement therefore attaches to the possibility of pregnancy, not to the severity of the symptom being treated or to how well the drug is working.
This is also one of the reasons a combined oral contraceptive frequently sits alongside an anti-androgen: it covers the contraception the anti-androgen requires. Which is a genuine combination — and a different one from the pairing this page opened with.
What most articles get wrong
Search the two names together and you will find protocols — stacks, combinations, sometimes with a third or fourth agent, presented as the way PCOS is treated.
There is no protocol in the guideline. There are indications, an order of preference within each, and a great deal of “consider”, “individual needs”, and “no particular preparation is superior”. The document reads like a decision tree rather than a recipe, because what is being treated differs from one person to the next.
The second common error is treating metformin as though it were for cycles and hair. It is prescribed for metabolic reasons, and the guideline explicitly prefers the pill for the cycle and hirsutism indications. Expecting the wrong outcome from a drug is how people conclude it has failed when it was never aimed at the thing they were watching.
What to ask at the next appointment
Two questions cover most of the confusion, and both have answers already sitting in your notes.
Which of these is for which problem? If the answer is “metabolic” for one and “hirsutism” for the other, the pairing resolves immediately and you know what each is supposed to change.
What should I expect to see, and by when? A metabolic indication is followed by a repeat test; a hirsutism indication is judged across months because the hair cycle says so. Knowing which clock you are on prevents the most common outcome of all — stopping something at week six because nothing appeared to be happening.
And if you are logging anything alongside this, log the date something started and the date anything changed. Six months is far past where memory is reliable, and the difference between “I think it helped a bit” and a dated record is the difference between a guess and evidence at the next appointment.